Literature DB >> 26427715

MSX2 mediates entry of human pluripotent stem cells into mesendoderm by simultaneously suppressing SOX2 and activating NODAL signaling.

Qingqing Wu1,2, Leisheng Zhang1,2, Pei Su1,2, Xiaohua Lei3, Xin Liu1,2, Hongtao Wang1,2, Lisha Lu4, Yang Bai1,2, Tao Xiong4, Dong Li5, Zhengmao Zhu6, Enkui Duan3, Erlie Jiang1,2, Sizhou Feng1,2, Mingzhe Han1,2, Yuanfu Xu1,2, Fei Wang7, Jiaxi Zhou1,2.   

Abstract

How BMP signaling integrates into and destabilizes the pluripotency circuitry of human pluripotent stem cells (hPSCs) to initiate differentiation into individual germ layers is a long-standing puzzle. Here we report muscle segment homeobox 2 (MSX2), a homeobox transcription factor of msh family, as a direct target gene of BMP signaling and a master mediator of hPSCs' differentiation to mesendoderm. Enforced expression of MSX2 suffices to abolish pluripotency and induce directed mesendoderm differentiation of hPSCs, while MSX2 depletion impairs mesendoderm induction. MSX2 is a direct target gene of the BMP pathway in hPSCs, and can be synergistically activated by Wnt signals via LEF1 during mesendoderm induction. Furthermore, MSX2 destabilizes the pluripotency circuitry through direct binding to the SOX2 promoter and repression of SOX2 transcription, while MSX2 controls mesendoderm lineage commitment by simultaneous suppression of SOX2 and induction of NODAL expression through direct binding and activation of the Nodal promoter. Interestingly, SOX2 can promote the degradation of MSX2 protein, suggesting a mutual antagonism between the two lineage-specifying factors in the control of stem cell fate. Together, our findings reveal crucial new mechanisms of destabilizing pluripotency and directing lineage commitment in hPSCs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26427715      PMCID: PMC4670987          DOI: 10.1038/cr.2015.118

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  66 in total

1.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

Review 2.  Signaling networks in human pluripotent stem cells.

Authors:  Stephen Dalton
Journal:  Curr Opin Cell Biol       Date:  2012-10-22       Impact factor: 8.382

3.  Wnt signaling promotes hematoendothelial cell development from human embryonic stem cells.

Authors:  Petter S Woll; Julie K Morris; Matt S Painschab; Rebecca K Marcus; Aimee D Kohn; Travis L Biechele; Randall T Moon; Dan S Kaufman
Journal:  Blood       Date:  2007-09-17       Impact factor: 22.113

4.  A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis.

Authors:  E W Jabs; U Müller; X Li; L Ma; W Luo; I S Haworth; I Klisak; R Sparkes; M L Warman; J B Mulliken
Journal:  Cell       Date:  1993-11-05       Impact factor: 41.582

5.  BMP4 promotes EMT and mesodermal commitment in human embryonic stem cells via SLUG and MSX2.

Authors:  Anne Richter; Lena Valdimarsdottir; Helga Eyja Hrafnkelsdottir; Johann Frimann Runarsson; Arna Run Omarsdottir; Dorien Ward-van Oostwaard; Christine Mummery; Gudrun Valdimarsdottir
Journal:  Stem Cells       Date:  2014-03       Impact factor: 6.277

6.  Induced pluripotent stem cell lines derived from human somatic cells.

Authors:  Junying Yu; Maxim A Vodyanik; Kim Smuga-Otto; Jessica Antosiewicz-Bourget; Jennifer L Frane; Shulan Tian; Jeff Nie; Gudrun A Jonsdottir; Victor Ruotti; Ron Stewart; Igor I Slukvin; James A Thomson
Journal:  Science       Date:  2007-11-20       Impact factor: 47.728

7.  Conditional alleles of Msx1 and Msx2.

Authors:  Hualin Fu; Mamoru Ishii; Ying Gu; Robert Maxson
Journal:  Genesis       Date:  2007-08       Impact factor: 2.487

8.  Insulin inhibits cardiac mesoderm, not mesendoderm, formation during cardiac differentiation of human pluripotent stem cells and modulation of canonical Wnt signaling can rescue this inhibition.

Authors:  Xiaojun Lian; Jianhua Zhang; Kexian Zhu; Timothy J Kamp; Sean P Palecek
Journal:  Stem Cells       Date:  2013-03       Impact factor: 6.277

9.  BMP-mediated functional cooperation between Dlx5;Dlx6 and Msx1;Msx2 during mammalian limb development.

Authors:  Maxence Vieux-Rochas; Kamal Bouhali; Stefano Mantero; Giulia Garaffo; Paolo Provero; Simonetta Astigiano; Ottavia Barbieri; Mariano F Caratozzolo; Apollonia Tullo; Luisa Guerrini; Yvan Lallemand; Benoît Robert; Giovanni Levi; Giorgio R Merlo
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

10.  Suppression of the SOX2 neural effector gene by PRDM1 promotes human germ cell fate in embryonic stem cells.

Authors:  I-Ying Lin; Feng-Lan Chiu; Chen-Hsiang Yeang; Hsin-Fu Chen; Ching-Yu Chuang; Shii-Yi Yang; Pei-Shan Hou; Nardnisa Sintupisut; Hong-Nerng Ho; Hung-Chih Kuo; Kuo-I Lin
Journal:  Stem Cell Reports       Date:  2014-01-23       Impact factor: 7.765

View more
  29 in total

1.  The homeobox transcription factor MSX2 partially mediates the effects of bone morphogenetic protein 4 (BMP4) on somatic cell reprogramming.

Authors:  Lilong Lin; Lining Liang; Xiao Yang; Hao Sun; Yuan Li; Duanqing Pei; Hui Zheng
Journal:  J Biol Chem       Date:  2018-08-10       Impact factor: 5.157

Review 2.  Pluripotent-derived Mesenchymal Stem/stromal Cells: an Overview of the Derivation Protocol Efficacies and the Differences Among the Derived Cells.

Authors:  Bruno Moisés de Matos; Anny Waloski Robert; Marco Augusto Stimamiglio; Alejandro Correa
Journal:  Stem Cell Rev Rep       Date:  2021-09-20       Impact factor: 5.739

3.  Ubiquitination of NF-κB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.

Authors:  Chune Ren; Xue Han; Chao Lu; Tingting Yang; Pengyun Qiao; Yonghong Sun; Zhenhai Yu
Journal:  Cell Death Differ       Date:  2021-08-31       Impact factor: 12.067

4.  MSX2 represses tumor stem cell phenotypes within oral squamous cell carcinomas via SOX2 degradation.

Authors:  Reziwan Keyimu; Maimaitituxun Tuerdi; Zhihe Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2021-08-26

5.  The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.

Authors:  Yuan Yin; Chuan-Ming Xie; Hua Li; Mingjia Tan; Guoan Chen; Rachel Schiff; Xiufang Xiong; Yi Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

6.  MSX2 inhibits the growth and migration of osteosarcoma cells by repressing SOX2.

Authors:  Yue Wu; Yi Jin; Norio Yamamoto; Akihiko Takeuchi; Shinji Miwa; Hiroyuki Tsuchiya; Zhijun Yang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

7.  Directly reprogramming fibroblasts into adipogenic, neurogenic and hepatogenic differentiation lineages by defined factors.

Authors:  Wei Wu; Yu-Qing Jin; Zhen Gao
Journal:  Exp Ther Med       Date:  2017-04-20       Impact factor: 2.447

8.  The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness.

Authors:  Eros Di Giorgio; Elisa Franforte; Sebastiano Cefalù; Sabrina Rossi; Angelo Paolo Dei Tos; Monica Brenca; Maurizio Polano; Roberta Maestro; Harikrishnareddy Paluvai; Raffaella Picco; Claudio Brancolini
Journal:  PLoS Genet       Date:  2017-04-18       Impact factor: 5.917

9.  Bone marrow-derived mesenchymal stem/stromal cells in patients with acute myeloid leukemia reveal transcriptome alterations and deficiency in cellular vitality.

Authors:  Leisheng Zhang; Ying Chi; Yimeng Wei; Wenxia Zhang; Fuxu Wang; Lei Zhang; Linglin Zou; Baoquan Song; Xing Zhao; Zhongchao Han
Journal:  Stem Cell Res Ther       Date:  2021-06-26       Impact factor: 6.832

10.  GCN5 Regulates FGF Signaling and Activates Selective MYC Target Genes during Early Embryoid Body Differentiation.

Authors:  Li Wang; Evangelia Koutelou; Calley Hirsch; Ryan McCarthy; Andria Schibler; Kevin Lin; Yue Lu; Collene Jeter; Jianjun Shen; Michelle C Barton; Sharon Y R Dent
Journal:  Stem Cell Reports       Date:  2017-12-14       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.